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Randomized controlled trials (RCT) are widely considered as the gold standard in generating 
evidence about the efficacy and safety of an experimental treatment. In practice, however, RCTs 
often suffer from non-compliance to the assigned treatment threatening the validity of the study 
results. Intent-to-treat (ITT) has been widely adopted as the standard analyses for such trials. 
However, under imperfect compliance, ITT validly estimates the treatment effectiveness instead 
of the treatment effect as-received (efficacy). Under the potential outcomes framework and certain 
assumptions, the treatment effect as-received may be represented by the Complier Average Causal 
Effect (CACE), the average treatment effects in the subgroups of compliers. Common methods 
used to estimate the CACE are As-Treated and Per-Protocol, both of which may introduce 
confounded comparisons between treatment arms due to the inherent differences between 
compliers and non-compliers. To provide valid estimates of CACE, causal inference methods such 
as propensity score (PS) and instrumental variables (IV)-based approaches have been proposed in 
the literature.  As long as an instrument exists, IV-based methods could provide inferences that are 
less model dependent. They do not necessarily require adjusting for covariates and avoids model 
selection and specification issues that PS-based methods face for the propensity-to-comply model. 
Due to random allocation, the randomization assignment often meets the assumptions imposed by 
an instrument and is widely accepted as a valid instrument in many situations. The most common 
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IV-based estimation method is 2-Stage-Least-Squares (2SLS). For binary outcome and binary 
treatment groups, estimating risk ratios or odds ratios have been the subject of many studies in the 
literature. When interest lies in estimating the risk difference (RD) as the CACE, a linear 
probability model in the second stage is commonly used. However, there is lack of consensus about 
what is the most suitable in the first stage where the observed treatment received is regressed to 
the treatment assignment (instrument). 
The goal of this study is to empirically investigate the different IV-based approaches to 
estimate the risk difference as CACE in RCTs with binary outcome and binary treatment group. 
We compared the performance of these methods with respect to bias, efficiency, and power and 
compare these to PP as the standard approach to estimate CACE. We also examined how their 
performance is affected by varying levels of compliance, effect size, sample size. In addition, we 
evaluated their statistical properties when measured confounders exist. 
We found that all the IV-based methods generally provide valid and very similar estimates, 
efficiency and power in the setting where there are no measured confounders, while the PP shows 
large bias in the presence of unmeasured confounders. However, when we can account for 
measured confounders, a 3-stage approach may provide more efficient estimates and yield higher 
power. As the compliance probability goes to 1 or as the sample size increases, the differences 
between the different IV-based methods become negligible.  
Public health significance: Results of RCTs are commonly used to implement policies or 
recommend guidelines to improve public health and patient care. Non-compliance however is 
common in RCTs and threatens the validity of its results. This study compares different strategies 
in providing correct estimates of treatment effect under imperfect compliance. This is critical in 
assessing the utility of an experimental treatment for adoption in clinical practice.  
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1.0  INTRODUCTION 
A randomize d clinical trial (RCT) is widely considered as the “gold standard” to evaluate 
the efficacy and safety of a treatment. The randomization ensures that treatment groups are 
comparable on both measured and unmeasured baseline variables which leads to unconfounded 
comparison between treatment arms. Moreover, a variety of rigorous guidelines ensure the validity 
of RCTs. For example, International Commission on Harmonization (ICH) guidelines provide a 
series of complete guidance for designing, conducting, recording, and reporting RCTs. These 
guidelines ensure that safe, effective, and high-quality medicines are developed and registered. 
In practice, however, RCTs often suffer from non-compliance in which subjects do not 
receive the assigned treatment as intended. Restricting the analyses to compliers may seem logical 
in estimating treatment efficacy as-received. However, this potentially introduces non-random 
selection bias which consequently undermine the validity of results. Thus, the occurrence of non-
compliance makes the causal inference hard to draw. For instance, an RCT conducted by Perkin 
MR, et al.[1] aiming to investigate the introduction of allergenic foods into the diet of breast-fed 
children was severely contaminated by noncompliance (only 32% compliance in the intervention 
group). When all subjects were analyzed as randomized, the results showed no difference between 
groups. However, when analysis was restricted to subjects who adhered to their assigned treatment, 
results showed a significant lower frequency of food allergy in the intervention arm versus the 
standard arm. The divergent conclusions from these two analyses made the interpretation of the 
study results difficult. Therefore, obtaining an unbiased estimate of treatment efficacy from RCTs 
with noncompliance is a critical problem. 
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A number of potential approaches have been proposed. They can be categorized into two 
groups: intention-to-treat (ITT) and non-ITT approaches.  
The principle of ITT analysis is that all participants should be analyzed in the group to 
which they had been assigned, irrespective of the treatment actually received. The resulting 
inference provides an estimate that reflects the effectiveness of the treatment, i.e., treatment effect 
in the real world setting. This can be important information to policy makers and health planners, 
but patients and clinicians generally want to know the treatment efficacy, i.e., treatment effect as-
received [2]. Under perfect compliance, treatment effectiveness and efficacy are equivalent. 
Several Non-ITT approaches have been used to estimate the treatment efficacy through 
adjustments for non-adherence. Two common Non-ITT methods are the As-Treated and the Per-
Protocol (PP). Both approaches aim to estimate the effect of treatment when actually received (as-
received treatment effect). The As-Treated analysis compares observed outcomes according to 
actual treatment received, while the PP analysis compares outcomes only in those subjects who 
were to compliant. However, because of inherent differences between compliers and non-
compliers, they tend to give biased estimates of treatment efficacy. 
Since none of the ITT, PP, or As-Treated can provide unbiased estimate in the presence of 
noncompliance, the possibility of estimating treatment effects only for compliers has been 
explored [3]. Angrist et al. [4] demonstrated that it is possible to estimate average causal treatment 
effect in compliers (CACE), given certain assumptions.  
A number of approaches have been developed to estimate CACE, such as instrumental 
variable (IV) based methods and propensity score (PS) based methods. Instrumental variable is an 
analytical technique that uses a variable associated with the factor under study but not directly 
associated with the outcome variable or any potential confounders [5]. IV analysis evaluate how 
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the instrument predicts the exposure and the outcome, then uses that information to understand 
how the exposure predicts the outcome [5]. Propensity score approach is an alternative, which is 
based on Frangakis and Rubin’s [6] principal stratification. The rationale is to fit a propensity score 
model based on one treatment condition in which the principal stratum membership can be 
identified, then apply this propensity score model to predict the principal stratum membership for 
individuals in the other treatment condition. After identifying individuals’ principal stratum 
membership in two arms, the treatment effects could be estimated in each stratum[7]. 
The IV techniques are appealing partly because they are easy to implement. Unlike the PS 
based method, the IV methods do not necessarily need to adjust for covariates, thus there is no 
model selection issue. A commonly acknowledged difficulty however is that valid instruments are 
uncommon and hard to find. In well-designed RCTs with noncompliance, this is often not an issue 
since the (randomized) treatment assignment often meets the assumptions of an instrument. With 
this well-established instrument, IV based methods have been widely applied in medical and 
epidemiological research[8-10].  
There has been extensive research[8-11] regarding the application of instrumental variable 
in clinical and epidemiology. However, most of them focused on continuous outcomes and 
continuous exposures. Though there are several reports for binary outcomes[12-15], most of them 
investigated how to estimate risk ratio or odds ratio. Little attention has been paid to the estimation 
of risk difference when both the exposure and outcome are binary. In RCTs, the exposure is 
typically binary (treatment versus control), and the outcome many times is binary, particularly 
when with regards to safety. Compared with risk ratio (RR) and odds ratio (OR), risk difference 
(RD) is more interpretable and straightforward. It is also known as Absolute Risk Reduction 
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(ARR) and its inverse is equal to the Number-Needed-to-Treat (NTT). In noninferiority studies, 
RD can often be more easily interpreted in a clinically meaningful way than RR [16]. 
There are several IV-based methods to estimate RD. Two-stage least square (2SLS) is the 
most commonly used approach. In the 1st stage, fitted values of the exposure variable are derived 
from a linear model against the instrument. In the 2nd stage, rather than use the exposure variable 
itself, the fitted values from the 1st stage are used in a linear model for the outcome to estimate the 
treatment effect. This method is well established in the setting of continuous outcomes and 
continuous exposures in the non-randomized data setting. To estimate RD when the outcome is 
binary, a linear probability model has been suggested for the 2nd stage[17]. Nevertheless when the 
exposure variable is binary, various models have been proposed for the first stage including a linear 
model, logistic-model, and a two-step logistic-linear model[18]. However, there is lack of 
consensus as to which method is the best, particularly in RCTs with non-compliance. 
The goal of this study is to empirically investigate the different IV-based approaches to 
estimate the risk difference as CACE in RCTs with binary outcome and binary treatment group. 
In the next chapter, we review the literature regarding treatment effect estimation methods in RCTs 
with noncompliance, mainly focus on IV-based methods. In chapter 3, we describe our simulation 
studies to empirically investigate the statistical performance of different IV-based approaches in 





2.0  LITERATURE REVIEW 
2.1 POTENTIAL OUTCOMES FRAMEWORK 
In the previous chapter, several potential approaches were mentioned to make causal 
inference in RCTs with noncompliance. In order to understand and compare these different 
approaches, it is helpful to think in the context of the Neyman-Rubin potential outcomes 
framework[4, 19, 20] and discuss Frangakis and Rubin’s idea of principal stratification[6]. 
The potential outcomes framework makes the causal effect inferences more 
straightforward and practical. This framework argues that there are two potential outcomes for an 
individual 𝑖, one is the value of the outcome the individual would experience if exposed to the 
treatment (𝑌𝑖(1)), the other is the value of the outcome the individual would experience if exposed 
to the control (𝑌𝑖(0)). The treatment effect for individual 𝑖 can be expressed as the difference 
between two potential outcomes, (𝑌𝑖(1) − 𝑌𝑖(0))  [21]. The average causal effect (ACE) or 
average treatment effect (ATE) is 𝐸(𝑌𝑖(1) − 𝑌𝑖(0)) = 𝐸(𝑌𝑖(1)) − 𝐸(𝑌𝑖(0)). This framework is 
based on one assumption, that is, the treatment assignment of one participant does not influence 
the outcomes of other participants. This is known as “stable unit-treatment value” assumption 
(SUTVA). If this assumption does not hold, the potential outcomes for an individual would not be 
just two, then causal inference is impossible. 
However in reality, it is only possible to observe one of the two potential outcomes for any 
given individual. We do not observe what would have happened if the individual had been 
randomly assigned to the other arm. Fortunately, randomization allows the causal effect to be 
estimated relatively easy. When the treatment assignment mechanism is random, the treatment 
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assignment is independent of outcomes. Also, the randomization ensures the construction of two 
comparable groups with respect to baseline variables whether measured or unmeasured. The 
observed average outcome in the experimental treatment group is taken as the estimate of the 
average outcome in all subjects had everyone received the experimental treatment. Similarly, the 
observed average outcome in the control group is taken as the estimate of the average outcome in 
all subjects had everyone received the control. The difference of the two estimates is the unbiased 
estimate of the ACE. The potential outcome framework and the randomization assignment 
mechanism provide a useful basis to estimate ACE. 
2.2 COMPLIER AVERAGE CAUSAL EFFECT   
In the real world, the purpose of randomization is often undermined due to imperfect 
compliance. Non-adherence happens when patients fail to follow the treatment they were assigned 
to, such as taking the comparison treatment instead of the assigned treatment or taking the assigned 
treatment but not according to the study protocol. Non-compliance potentially introduces non-
random selection bias to RCTs. The most commonly used statistical methods ITT, PP, and AT 
often generate biased estimate for treatment efficacy. Angrist et al. [4] proposed that under certain 
assumptions, the ACE in the subgroup of compliers or CACE represents the treatment efficacy. 
To better understand and compare these different approaches, it is necessary to first understand 
Frangakis and Rubin’s idea of principal stratification[6].  
Frangakis and Rubin[6] proposed the concept of principal stratification, which classify 
participants in RCT with noncompliance as one of four types, compliers (C), never-takers (NT), 
always-takers (AT), and defiers (D) (Figure 1). Let 𝑇𝑖 be the indicator of randomized treatment 
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assignment, 𝑇𝑖 = 1 if the i
th subject is randomized to the experimental treatment group, and 𝑇𝑖 =
0 if randomized to the control group, for 𝑖 = 1,2, … . , 𝑁. Compliance status is assumed to be all-
or-nothing. Let 𝑅𝑖 denote the indicator of treatment received if randomized to 𝑇𝑖 so that 𝑅𝑖(𝑇𝑖) =
1 if the experimental treatment is received and 0 if the control is received. Compliers are people 
who would receive whatever treatment is assigned [𝑅𝑖(1) = 1, 𝑅𝑖(0) = 0]; never-takers would 
only receive the control regardless of the treatment assignment [𝑅𝑖(1) = 𝑅𝑖(0) = 0]; always-
takers would only receive the experimental treatment [𝑅𝑖(1) = 𝑅𝑖(0) = 1]; and defiers would take 
the treatment opposite to the assigned treatment [𝑅𝑖(1) = 0, 𝑅𝑖(0) = 1]. The latent classes are 
determined prior to randomization, they can be viewed as pre-treatment covariates having the same 
distribution in the two treatment arms due to randomization assignment mechanism. When we 
assume that there are no defiers (monotonicity), Figure 1 shows the principal strata in both arms. 
Since each class of patients are equally distributed across treatment arms, the proportion of AT 
can be estimated from the observed proportion who received the experimental treatment in the 
control group. Similarly, the proportion of NT can be estimated in the treatment group. Then, the 
proportion of compliers can be estimated from the difference in the proportions in each arm who 
received the assigned treatment, i.e., 𝑃(𝐶) = 𝑃(𝐶 ∪ 𝐴𝑇) − 𝑃(𝐴𝑇) = 𝑃(𝐶 ∪ 𝑁𝑇) − 𝑃(𝑁𝑇).   
For simplicity, we assume a common RCT design in which participants in the control group 
do not have access to the experimental treatment, i.e. 𝑅𝑖(0) = 0 for all i. Thus, always takers do 
not exist. In this context, the latent classes are reduced to two strata based on binary 𝑇 and binary 
𝑅. These two classes are compliers (𝐶) [𝑅𝑖(1) = 1, 𝑅𝑖(0) = 0] and never takers (𝑁𝑇) [𝑅𝑖(1) =
0, 𝑅𝑖(0) = 0] which we would refer to as non-compliers (𝑁𝐶). Figure 2 shows the principal strata 
in each arm, where 𝐴 and 𝐴′ denote the average outcome for compliers in the treatment group and 
the control group respectively; likewise 𝐵 and 𝐵′ denote the average outcome for non-compliers 
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in the treatment group and the control group respectively. Note that 𝐴 and 𝐵 are both observable 
in the treatment arm, but only the combined (𝐴′ + 𝐵′) is observable in the control arm. The 
principal stratification provides a useful tool to estimate causal effect of treatment in the subgroup 
compliers, namely the CACE. With the knowledge of principal stratification, it is easier to 
understand the advantage and disadvantage of different approaches to make casual effect in the 
setting of RCT with noncompliance.  
 
Figure 1. Principal strata in RCTs with noncompliance 
 
 
Figure 2. Simplified principal strata in RCTs with noncompliance 
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One potential solution to estimate average treatment effect is ITT. The ITT principle has 
long been mandated by the Food and Drug Administration (FDA) as the primary analysis strategy 
for industry clinical trials[22]. It aims to estimate the effect of treatment as assigned, including all 
randomized patients in the groups to which they were randomly assigned, regardless of whether 
or not the patient received the allocated treatment[23] [(𝐴 + 𝐵)̂  - (𝐴′ + 𝐵′)̂ ]. The advantage of 
ITT analysis is that it maintains the baseline comparability achieved by the randomizing process. 
The resulting inference provides an estimate that reflects the effectiveness of the treatment in terms 
of the public health benefits of administering the treatment in the community, where non-
compliance is inevitable in actual clinical practice. Nevertheless, ITT method usually does not 
generate a valid estimate of the treatment effect on individual patients (the effect of treatment as 
delivered or as received), especially when the non-compliance rate is high. It usually leads to 
conservatively biased estimate of as received treatment efficacy, because of dilution due to 
noncompliance. This could be acceptable for a superiority trial[24] as the bias is towards the null. 
However, it may be problematic in a non-inferiority trial, since the non-inferiority conclusion may 
have resulted from dilution of treatment difference due to noncompliance rather than the actual 
therapeutic similarities between experimental treatment and standard therapy. 
Several Non-ITT approaches have been used to estimate the treatment effect through 
adjustments for non-adherence. Two common non-ITT methods are the As-Treated analysis and 
the PP analysis. Both approaches aim to estimate the effect of treatment when actually received 
(as-received treatment effect). The As-Treated analysis compares observed outcomes according to 
treatment received 𝐸(𝐴) − 𝐸(𝐵 + 𝐴′ + 𝐵′), while the PP analysis compares outcomes only in 
those subjects who were observed to be compliant 𝐸(𝐴) − 𝐸(𝐴′ + 𝐵′). Both methods however are 
susceptible to selection bias. Both analyses involve the comparison of two treatment groups with 
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potentially different underlying patient characteristics[25]. When noncompliance is random and 
independent of outcomes (ignorable), both solutions could generate valid treatment effect estimate. 
However, noncompliance cannot usually be assumed to be random. It may be related to many 
factors such as adverse events and prognosis. These two methods are invalid to estimate treatment 
efficacy.  
Unbiased estimate of the CACE (𝐴 − 𝐴′) is (?̂? − ?̂?′). However, ?̂?′ cannot be directly 
calculated from the observed data. Angrist et al. [4] demonstrated that under certain assumptions, 
the observed data can be used to estimate the CACE.  
2.3 INSTRUMENTAL VARIABLE 
One way to obtain valid estimates of CACE is through the use of instrumental variables 
(IV) [4]. IVs are designed to deal with problems of endogeneity (i.e. the explanatory predictor is 
correlated with the error term.) by isolating the variability in the predictor that is causally related 
to the outcome[4, 5, 12, 26]. IV has been widely used in RCT with noncompliance[27] or 
observational studies[12, 28] to estimate the causal effect of treatment or exposure to risk factor 
when there is unmeasured confounder. In the context of randomized trials, the IV approach can 
yield unbiased treatment effect estimation in the presence of unmeasured confounders, given 
certain assumptions are met. This method estimates the CACE in a way that preserve the balance 
in patient characteristics from randomization[25].  
A key component of the IV approach is to identify the instrument. A valid instrument must 
meet three assumptions [12]. Figure 3 shows a causal diagram that describes the following 
assumptions that IV must meet [4]:  
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(1) the IV is associated with the treatment;  
(2) the IV is independent of unmeasured confounders;  
(3) the IV affects the outcome only through the treatment.  
            In the case of randomized clinical trials with noncompliance, the randomized treatment 
assignment satisfies these three assumptions. First, the treatment received (𝑅) is affected but not 
fully determined by the treatment assignment (𝑇)  (assumption 1); Second, the treatment 
assignment is randomized, so the treatment assignment is independent of unmeasured confounders 
(𝑈)(assumption 2); Furthermore, because patients and outcome assessors are usually blinded to 
the randomized treatment assignment, one can assume that it would not have an effect on the 
outcome (𝑌)  beyond that due to the treatment actually received (assumption 3). Therefore, 
treatment assignment can generally be used as the instrument to account for unmeasured 
confounders in randomized clinical trials with non-compliance.  
 
Figure 3. Graphical representation of a trial with noncompliance, with randomization as an instrumental 
variable for the treatment received 
 
 
In addition to the identification of instrument, the following assumptions[3] are necessary 
in order to obtain an unbiased estimate of CACE via the IV-based method.  
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Assumption 1 (randomization): Treatment assignment is random. Randomization supports 
the second assumption of IV (the IV is independent of unmeasured confounders). In RCT, 
treatment assignment is independent of any measured or unmeasured confounders. 
Assumption 2 (stable unit treatment value, SUTVA): Potential outcomes for each person 
are unrelated to the treatment status of other individuals. This assumption allows the application 
of potential outcome framework, which makes the causal effect estimate straightforward and 
practical.  
Assumption 3 (exclusion restriction): For compliers and noncompliers, the distributions of 
the potential outcomes are independent of the treatment assignment, that is, the potential outcome 
depends on treatment assignments only through the actual treatment received. This assumption is 
equivalent to the third assumption of IV (the IV affects the outcome only through the treatment). 
Assumption 4 (monotonicity): There are no defiers. This assumption requires that for every 
subject who chooses not to take the experimental treatment when randomized to it, he or she will 
not try to obtain the experimental treatment if randomized to the comparison group.[29] In 
randomized clinical trials, especially blinded RCT, it is reasonable to assume that there is no 
defiers.  
Assumption 5 (non-zero average causal effect of instrument on treatment): The average 
causal effect of instrument on treatment is not equal to zero. It means that there is a causal pathway 
from treatment assignments to treatment received. This assumption is identical to the first 
assumption of IV (the IV is associated with the treatment). 
There has been extensive research on the theory and application of instrumental variables 
in clinical and epidemiologic studies[8-11]. Most of them applied the IV method in the setting of 
continuous outcomes and continuous exposures.  
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When both exposure and outcome are continuous, the most commonly used technique for 
instrumental variable analysis is the 2SLS method[18]. This method splits the estimation into two 
stages. In the first stage, the treatment variable is regressed on the instrument and the predicted 
treatment is obtained from the fitted model; the second stage fits the outcome regression, replacing 
the treatment variable with their predicted values obtained from the first stage. The mathematical 
proof of 2SLS is as the following: 
Let 𝑌 denote the outcome, 𝑅 is an endogenous exposure, 𝜀 is the error term. A simple 
linear model is:   
𝑌𝑖 = 𝛾0 + 𝛾1𝑅𝑖 + 𝜀𝑖     (1), 








Let 𝑇 denote the instrumental. 𝑇 is supposed to be linearly related to 𝑅, and independent 
of the unmeasured confounder, that is, 𝐶𝑜𝑣(𝑇, 𝜀)  = 0, 𝐶𝑜𝑣(𝑇, 𝑅)  ≠  0.  
𝐶𝑜𝑣(𝑇, 𝑌) =  𝐶𝑜𝑣(𝑇, 𝛾0 + 𝛾1𝑅 + 𝜀) 
                                                       = 𝛾1𝐶𝑜𝑣(𝑇, 𝑅) + 𝐶𝑜𝑣(𝑇, 𝜀) 






The 2SLS includes two steps: 
𝑆𝑡𝑒𝑝 1: 𝑅𝑖 = 𝛼0 +  𝛼1𝑇𝑖  +  𝜂𝑖          (2) 
𝑆𝑡𝑒𝑝 2: 𝑌𝑖 =  𝛽0 +  𝛽1?̂?𝑖  + ν𝑖           (3) 
Since 𝐶𝑜𝑣(?̂?, ν) = 0, 𝛽1̂ is unbiased estimator of 𝛽1. 
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𝐶𝑜𝑣(?̂?0 +  ?̂?1𝑇, 𝑌)





Hence, the 2SLS method can produce unbiased estimate for the effect of an endogenous 
exposure.  
When the outcome is binary, most of the research investigated how to estimate RR or OR. 
A number of methods have been reported to estimate RR and OR, such as 2-stage logistic 
model[30, 31], probit structural equation models[32], 3-stage model[33], and two-stage residual 
inclusion method[34]. However, little attention has been paid to the estimation of RD when both 
the exposure and outcome are binary. 
We consider 3 IV-based approaches to estimating RD in RCT with imperfect compliance, 
when the treatment and outcome are both binary: 2SLS, 2-stage logistic/linear approach (LG-LM), 
and 3-stage approach. 
2.3.1 2SLS 
The most commonly used technique for instrumental variable analysis is the 2SLS [18]. 
The 2SLS approach has been justified and widely used in the setting of continuous outcomes [35]. 
In the case of dichotomous exposures and outcomes, we can mathematically demonstrate that 
2SLS can produce a RD estimate. In a linear regression model, the ordinary least squares method 
can be used to estimate the parameters, and this method produces best linear unbiased estimators 
of 𝛾0 and 𝛾1 [36]. It is known that the procedure, to obtain the unbiased estimator of 𝛾0 and 𝛾1, 
does not require assumptions of normality nor constant variance. Thus, if the research interest is 
to make estimation about the parameters, the normality and constant variance assumptions are not 
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required. In the case of binary outcome coded as 0 or 1, the outcome variable is not normally 
distributed, but the mean is equal to the proportion. Therefore, the OLS method can be used to 
analyze a binary response[16], and the estimate of RD is the regression coefficient 𝛾1 . 
Previously, we have proved that the 2SLS method can produce unbiased estimate for the 
effect of an endogenous exposure in the setting of continuous exposures and outcomes. Similarly, 
we can show that the 2SLS method can also generate unbiased estimate of risk difference when 
both the treatment and outcome are dichotomous. 
Suppose that the 𝑅, 𝑇, and 𝑌 are all dichotomous in equation (1), (2) and (3). A simple 
linear model can be fit between 𝑌 and 𝑇:   
𝑌𝑖 =  𝜅0 +  𝜅1𝑇𝑖  +  ω𝑖      (4) 




















In the setting of binary instrument, exposure and outcome, the numerator is the difference 
in mean outcome between 𝑇 = 0 and 𝑇 = 1, that is,  P(𝑌 = 1| 𝑇 = 1)  −  P(𝑌 = 1| 𝑇 = 0), and 
the denominator is the difference in mean exposure between 𝑇 = 0 and 𝑇 = 1, that is, P(𝑅 =
1| 𝑇 = 1)  −  P(𝑅 = 1| 𝑇 = 0). When the subjects in the control group do not have access to the 




P(𝑌=1| 𝑇=1) − P(𝑌=1| 𝑇=0)
P(𝑅=1| 𝑇=1) 
 
We have proved that  𝛽1 = 𝛾1, Thus, 
𝛽1 = 𝛾1 =
P(𝑌 = 1| 𝑇 = 1) −  P(𝑌 = 1| 𝑇 = 0)
P(𝑅 = 1| 𝑇 = 1) 
 
The assumptions of normality or constant variance are assumed when other statistical 
procedures are made, such as hypothesis testing and confidence interval construction. In the 
context of binary outcomes and exposures, the statistical inference (hypothesis testing or 
confidence interval) is not valid since the error structure for a binary outcome does not follow 
normal distribution. Cheung [16] proposed a modified least-squares regression approach to 
estimate RD by the OLS regression method accompanied by statistical inference based on the 
Huber-White robust estimate of variance. He demonstrated that this approach produces valid 
inferences.  
2.3.2 LG-LM 
Linear models in the 2SLS may not be natural model choices for binary outcome and 
exposure since the fitted values are not bounded by (0,1). Even so, in the 2nd stage (outcome 
regression), a linear model provides a direct estimate of RD through the regression coefficient 
associated with the exposure, making it a justifiable choice over common models for binary data 
such as logistic or probit regrssion. In the 1st stage however, we care less about the interpretation 
of the coefficients and hence we are not forced to use a linear model. A logistic model provides a 
natural alternative in regressing the exposure on the instrument to obtain fitted exposure values. 
These can then be used in stage 2 to estimate RD. As with the 2SLS approach, the standard errors 
could be calculated based on the Huber-White robust estimate of variance. Rassen et al [18] 
 17 
proposed this two-stage modeling with the first stage logistic and the second stage ordinary least 
square. The confidence intervals in their study were based on bootstrapped standard errors. They 
tested this model in three observational studies and observed little difference in point estimate or 
precision between estimates from 2SLS models and LG-LM model. 
2.3.3 3SLS 
Considering the model misspecification issue when using 2SLS estimation in the setting 
of binary exposures and outcomes, that is, the predicted value could be out of the 0-1 range, fitting 
a logistic model in the first stage may be reasonable. The 2-stage LG-LM offers an alternative 
solution to model misspecification in the first stage. However, the misspecification of the logistic 
model in the first stage, i.e. the first stage logistic model is incorrect, would lead to inconsistent 
estimate in the second stage [18]. Whereas consistent estimates would always be generated from 
2SLS. As a result, Angrist [37] proposed a 3-stage method:  
(1) use a logistic regression of treatment (𝑅) on instrument (𝑇) to obtain the predicted 
probability ?̂? that 𝑅𝑖 =  1;  
(2) a linear first stage model is estimated using ?̂? as the instrument instead of 𝑇;  
            (3) the outcome linear probability model is fitted to obtain estimate of the risk difference. 
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3.0   EMPIRICAL STUDY 
In this chapter, we conducted two sets of simulation studies to compare the empirical 
performance of the three previously described IV-based methods and the PP method in estimating 
the CACE for RCTs with noncompliance. We assumed that the treatment (𝑇) and outcome (𝑌) are 
binary. We also assume that subjects assigned to the control group did not have access to the 
treatment. Therefore, the number of principal stratum is reduced to two: compliers (𝐶) and non-
compliers (𝑁𝐶). In the first set of simulation studies, we investigated the performance of IV-based 
methods when there is no measured confounder in the RCTs, while in the second simulation study, 
we examined the behavior of IV methods when accounting for a measured confounder. We varied 
the sample size, compliance probability, and effect size.   
3.1 NO MEASURED CONFOUNDER 
In this section, we consider the situation when there is no measured confounder between 
the treatment received and the outcome. This indicates that the noncompliance is due to some 
unmeasured confounders, which in theory could be corrected by IV approaches. We initially 
compared the three IV methods and the PP approach using a fixed sample size. We then expanded 
the simulation scenarios by including wider levels of compliance, effect size, and sample size 
albeit imposing a simplifying assumption between complier and non-complier outcomes.    
 19 
3.1.1 IV-based methods and PP with fixed sample size 
In this set of simulations, we make a less restrictive assumption that the average outcome 
between 𝐶  and 𝑁𝐶  under control were different, i.e. the noncompliance is not random. This 
assumption reflects the real-world situation of noncompliance, generally non-adherents are less 
healthy and less health conscious than adherents. We took the case where the unmeasured 
confounder (𝑈) is binary. The confounder predicts the compliance stratum (𝐶 or 𝑁𝐶). Figure 4 
shows a causal diagram that illustrates the relationship between these variables. The 𝑌  is 
dependent on 𝑈 and 𝑅. Since individuals in the control group could not access treatment, the 
compliance strata (𝑆) include two strata: 𝐶 and 𝑁𝐶, and the status of compliance is predicted by 
𝑈. The 𝑅 is dependent on the 𝑇 and 𝑆, i.e. only if subjects are randomly assigned to the treatment 
group and they are compliers, they will receive treatment, otherwise, they will not. In fact, 𝑅 =
𝑇𝑆. The parameter of interest, CACE, is represented by 𝛾1. We used a linear probability model for 
the outcome so that 𝛾1 represents the risk-difference.  
 
 
Figure 4. Graphical representation of a RCT with noncompliance, with randomization as an instrumental 





Based on the relationship between the variables in Figure 4, the following factors in the 
current simulation study were considered: 
(1) Sample size (𝑁): 500; 
(2) Treatment assignment probability (𝜋𝑇 ): the probability to be assigned to the treatment 
group, 𝜋𝑇 was set to 0.5; 
(3) Binary unmeasured confounder (𝑈 ): 𝑈  was drawn from a Bernoulli distribution with 
parameter 𝜋𝑈 in the treatment group and the control group. Here, 𝜋𝑈 was set to 0.5; 
(4) To generate the compliance strata (𝑆), the following semi-parametric linear probability 
model was applied: 
𝑆 =  𝜃0 + 𝜃1𝑈 +  𝜀1 , where 𝐸(𝜀1) =  0; 𝑈 = {0,1}; 𝑆 = {0,1}. 
Then, 
𝐸(𝑆|𝑈) =  𝜃0 + 𝜃1𝑈 
𝑆  was drawn from a Bernoulli distribution with probability equals to 𝐸(𝑆|𝑈)  in the 
treatment group and the control group.  
(5) The treatment received (𝑅) was generated based on the equation:  
𝑅 =  𝑆𝑇 
that is, 𝑅 =  1 if and only if 𝑆 = 1 and 𝑇 = 1 .  
(6) The binary outcome (𝑌) was generated based on the following semi-parametric linear 
probability model: 
𝐸(𝑌 = 1|𝑅, 𝑈) =  𝛾0 + 𝛾1𝑅 + 𝛾2𝑈, where 𝑈 = {0,1};  𝑅 = {0,1}; 𝑌 = {0,1}. 
The outcome 𝑌  was drawn from a Bernoulli distribution with probability equals to 
𝐸(𝑌 = 1|𝑈, 𝑅). 
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We investigated the effect of changes in compliance probability levels (low, high) and risk 
difference levels (none, low, high) on the estimation properties using four approaches, namely, 
three IV-based methods and PP approach. The parameter settings for each scenario are shown in 
Table 1. Scenarios 1-3 represent low compliance (average compliance probability = 0.55) and 
Scenarios 4-6 represent high compliance (average compliance probability = 0.8). For each 
compliance setting, we varied the true risk difference (CACE) from no effect (𝛾1 = 0) to as high 
as 0.3. For each scenario, 1000 simulated datasets were generated. 
 
Table 1. No measured confounder simulation 1 scenarios 
Scenario Compliance Effect 𝜽𝟎 𝜽𝟏 𝜸𝟎 𝜸𝟏 𝜸𝟐 
1  
Low 
None 0.8 -0.5 0.4 0.00 -0.2 
2 Low 0.8 -0.5 0.4 0.15 -0.2 
3 High 0.8 -0.5 0.4 0.30 -0.2 
4  
High 
None 0.9 -0.2 0.4 0.00 -0.2 
5 Low 0.9 -0.2 0.4 0.15 -0.2 
6 High 0.9 -0.2 0.4 0.30 -0.2 
 
Analysis: Estimating risk difference 
RD was estimated for each simulated dataset using three IV-based approaches: (1) 2SLS, 
(2) 2-stage LG-LM, and (3) 3-stage LG-LM-LM. The ivreg command from R package AER was 
used for fitting 2SLS. Here, robust standard error (R packages “sandwich” and “lmtest” were 
applied, type= “HC4”) was required in the last stage of each method. Furthermore, we compared 
RD estimates from the PP method. Because individuals in the control group do not have access to 
the treatment, RD in the PP was estimated as the difference between the compliers in the treatment 
group and all the subjects in the control group. 
To evaluate each approach’s performance, the bias, relative bias, average of standard error 
(ASE), empirical standard error (ESE), coverage probability (CP), and power for assessing the 
treatment effect among compliers were examined. Relative bias was calculated as the mean of the 
 22 
bias in each scenario divided by the corresponding true risk difference. Coverage probability is 
defined as the proportion of replications where the true parameters values are covered by the 
nominal 95% confidence interval of the parameter estimates[38]. Power is defined as the 
proportion of times that each method rejects the null hypothesis (the risk difference is equal to 0) 




In terms of the five evaluation parameters, the tested three IV-based methods generated 
valid estimates with almost identical performances. First, the three IV-based methods led to almost 
identical unbiased estimates (Figure 5), the relative bias ranged from 0.5% to 1% in all cases. The 
power (Figure 6) results showed that when the risk difference was zero, the type I error of three 
IV-based methods was about 5%. As the risk difference increases, the power goes up. When the 
risk difference was as high as 0.3, the power was close to 1. From Figure 8, we can see that the CP 
was very close to 95% in all cases when using the IV-based methods. With respect to ESE (Figure 
7) and ASE, the values were almost identical in three IV methods, both the ESE and ASE decreased 
as the compliance probability grew. Also, the ASE generated from all three IV methods were all 
very close to the corresponding ESE.  
In contrast, the performance of PP was not as good as the three IV-based methods. The 
relative bias was large when PP method was applied, especially when the compliance probability 
was low. For example, the relative bias was as high as 31% when the compliance probability was 
0.55, the risk difference was 0.15. But when the compliance probability increased to 0.8, the 
relative bias dramatically decreased to 7%. The power results showed that when the risk difference 
was zero, the type I error of PP method was around 16% when the compliance probability was 
low. The type I error reduced to 5% when the compliance probability increased to 0.8. The CP was 
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less than 85% when compliance probability was as low as 0.55. However, when the compliance 
probability increased to 0.8, the CP was around 95%. The ESE and ASE results were very similar 
to that of IV methods, whereas PP had smaller ASE and ESE than three IV methods, especially 
when the compliance probability was low. This indicates that the PP method was more efficient 
than IV-based methods.  
Concerning the impact of compliance probability on each method’s performance, we can 
see that PP method was more sensitive to compliance probability than IV methods. The relative 
bias of PP greatly decreased as the compliance probability increased, while the relative bias of IV 
methods did not show this trend, it varied around 0.5% to 1%. The influence of compliance 
probability on power depends on risk difference, when the risk difference is none or high, the three 
IV methods’ power was almost identical, on the other hand, when the risk difference was low, 
increasing the compliance probability led to stronger power. However, for the PP method, the 
compliance probability had greater influence when the risk difference was none, that is, increasing 
the compliance resulted in smaller type I error. The CP of IV methods keeps constant when the 
compliance probability change, whereas the CP of PP improved from about 85% to around 95% 
when the compliance probability changed from low to high. All four methods’ ESE and ASE 
decreased as the compliance probability increased.   
Comparing the influence of risk difference on each method’s behavior, we can see that 
relative risk of IV methods was not very sensitive to risk difference when the compliance is low, 
but when the compliance is high, the relative risk decreased as the risk difference got larger. For 
PP method, the relative bias showed a decreasing trend as the risk difference increasing. The power 
of these four methods all revealed an increasing direction as the risk difference increased, the PP 
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method achieved high power (over 95%) when the risk difference was 0.15. As for ASE, ESE and 
CP, all four methods did not show strong sensitivity to risk difference.  
To sum up, the three IV-based methods can all provide unbiased estimates with the settings 
in the current simulation, and their performances were almost identical in terms of relative bias, 
power, ESE, ASE, and CP. However, the estimate obtained from PP method is highly biased when 
the compliance probability is relative low. On the other hand, as the compliance probability 




Figure 5. Absolute relative bias of IV-based methods and PP in each scenario  
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Figure 6. Power of IV-based methods and PP in each scenario 
 
  
Figure 7. ESE of IV-based methods and PP in each scenario using 
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Figure 8. CP of IV-based methods and PP in each scenario 
3.1.2 Expanded comparisons for IV-based methods 
In this section, we carried out a series of simulation to investigate the sensitivity of the 
three IV-based methods to the variation of factors, namely, sample size, compliance probability, 
and risk difference. We varied the sample size and included more levels of compliance and effect 
sizes. For simplicity, we assume that noncompliance was unrelated with prognosis, that is, the 
potential outcomes for compliers and noncompliers under control were the same.  
Data generation 
We considered the following factors in the simulation study design: 
(1) Sample size (𝑁): three levels of sample size were considered -- 100, 250, 500;  
(2) Treatment assignment probability (𝜋𝑇): the probability one is assigned to the treatment 
group. 𝜋𝑇 was set to 0.5. 
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(3) Compliance probability (𝜋𝑅 ): the probability of compliance if one is assigned to the 
treatment group. We assessed four levels of 𝜋𝑅 -- 0.50, 0.65, 0.8, 0.95; 
(4) Risk difference (△): six levels of risk difference were evaluated -- 0.00, 0.05, 0.1, 0.15, 0.2, 
0.25; 
(5) The baseline effect (𝜋0): the probability of success when one does not receive treatment. 
𝜋0 was set to 0.5. 
Thus, we have 72 different combination of scenarios (Table 2.) For each scenario, 1000 
simulated datasets were generated. Each dataset was generated as follows: 
1. The binary treatment assignment indicator 𝑇𝑖 for the 𝑖𝑡ℎ subject is simulated: 𝑇𝑖 ~ Bernoulli 
(P= 𝜋𝑇), where 𝜋𝑇=0.5. 
2. The treatment received indicator 𝑅𝑖 for the 𝑖
𝑡ℎ subject is draw from Bernoulli distribution: 
𝑅𝑖 ~ Bernoulli (𝑃 = 𝜋𝑅) 𝑇𝑖 
that is, for the 𝑖𝑡ℎ subject who is assigned to the control group (𝑇𝑖 = 0), the 𝑅𝑖 is always 0, 
if assigned to the treatment group (𝑇𝑖 = 1), then 𝑅𝑖 ~ Bernoulli (𝑃 = 𝜋𝑅). 
3. The binary outcome 𝑌𝑖 for the 𝑖
𝑡ℎ subject is simulated:                                
𝑌𝑖 ~Bernoulli (𝑃 =  𝜋0) I(𝑅𝑖 = 0) 
𝑌𝑖  ~Bernoulli (𝑃 =  𝜋0 +△) I(𝑅𝑖 = 1), 
that is, if the 𝑖𝑡ℎ subject does not receive the treatment (𝑅𝑖 = 0), the subject’s probability 






Table 2. No measured confounder simulation 2 scenarios 
































































The relative bias, empirical standard errors, power and coverage probabilities are shown in 
Figures 9, 10, 11, and 12 respectively. In general, we observed the same patterns as in the previous 
simulations. The three IV-based methods have nearly identical performance. They yield estimates 
with low relative bias and confidence intervals and type I error rate close to nominal levels. 
Relative bias, efficiency (in terms of lower ESE), and power improve with higher sample sizes or 
higher compliance probabilities. 
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Figure 9. Absolute relative bias of IV-based methods in each scenario 
 
 
Figure 10. ESE of IV-based methods in each scenario 
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Figure 11. Power of IV-based methods in each scenario  
 
Figure 12. CP of IV-based methods in each scenario 
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3.2 ACCOUNTING FOR A MEASURED CONFOUNDER 
In this section, we assume that a measured confounder between the treatment received and 
outcome exists. The aim was to investigate the statistical properties of CACE estimation when 
measured confounder was adjusted for in the three IV-based methods, especially in terms of 
efficiency. Furthermore, we examined the performance of 2SLS when the measured confounder 
was adjusted for or not. The causal diagram (Figure 13) is similar to that in the previous section, 
except for an additional measured confounder 𝑋. Here, the compliance strata are predicted by both 
the measured and unmeasured confounder. Outcome is dependent on 𝑋, 𝑈, and 𝑅. 
 
 
Figure 13. A RCT with noncompliance, when both measured and unmeasured confounders exist 
 
Data generation 
Based on the relationship shown in Figure 13 we simulated 24 scenarios to compare these 
three methods, varying the sample size, compliance probability and risk difference. The simulation 
procedure was conducted as follows:  
(1) Sample size (𝑁): 100, 250, 500, 1000; 
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(2) Treatment assignment probability (𝜋𝑇 ): the probability to be assigned to the treatment 
group, 𝜋𝑇 was set to 0.5; 
(3) Binary unmeasured confounder (𝑈 ): 𝑈  was drawn from a Bernoulli distribution with 
parameter 𝜋𝑈 in the treatment group and the control group. Here, 𝜋𝑈 was set to 0.5; 
(4) Continuous measured confounder (𝑋): 𝑋 was drawn from a uniform distribution: 
𝑋~𝑈𝑛𝑖𝑓𝑜𝑟𝑚(1,3) 
(5) The compliance strata (𝑆) was draw from a Bernoulli distribution with parameter 𝑝1, which 
is a function of both 𝑋 and 𝑈. 
𝑆~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝1 =
exp (𝜃0 + 𝜃1𝑈 + 𝜃2𝑋)
1 + exp (𝜃0 + 𝜃1𝑈 + 𝜃2𝑋)
) 
(6) The treatment received (𝑅) was generated based on the equation:  
𝑅 =  𝑆𝑇 
            that is, 𝑅 =  1 if and only if 𝑆 = 1 and 𝑇 = 1 .  
(7) The binary outcome (𝑌) was generated based on the following semi-parametric linear 
probability model:  
𝐸(𝑌 = 1|𝑅, 𝑈, 𝑋) =  𝛾0 + 𝛾1𝑅 + 𝛾2𝑈 + 𝛾3 log(𝑋) 
Here, 𝑋 was log transformed to ensure that the probability is bounded between 0 and 1. 
Then, 
𝐸(𝑌 = 1|𝑅, 𝑈, 𝑋) =  𝛾0 + 𝛾1𝑅 + 𝛾2𝑈 + 𝛾3 log(𝑋) 
The outcome 𝑌  was drawn from a Bernoulli distribution with probability equals to 
𝐸(𝑌|𝑅, 𝑈, 𝑋). 
In this simulation study, we investigated 24 scenarios with different sample size, 
compliance probability and risk difference. The parameter settings for each scenario are shown in 
Table 3. Scenario 1-3 represent low compliance (average compliance probability at 0.5), while 
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scenario 4-6 represent high compliance (average compliance probability at 0.9). For each 
compliance setting, the risk difference (𝛾1) ranged from none (0.00) to low (0.15) to high (0.3). 
Scenario 1-6 were repeated for different sample size, 𝑁 = 250, 500, 1000. For each scenario, 1000 
simulated datasets were generated. 
 
Table 3. Accounting for a measured confounder simulation scenarios 
Scenario Compliance Effect N* 𝜽𝟎 𝜽𝟏 𝜽𝟐 𝜸𝟎 𝜸𝟏 𝜸𝟐 𝜸𝟑 
1  
Low 
None 100 7 3 -4 0.35 0.00 -0.1 0.25 
2 Low 100 7 3 -4 0.35 0.15 -0.1 0.25 
3 High 100 7 3 -4 0.35 0.30 -0.1 0.25 
4  
High 
None 100 11 3 -4 0.35 0.00 -0.1 0.25 
5 Low 100 11 3 -4 0.35 0.15 -0.1 0.25 
6 High 100 11 3 -4 0.35 0.30 -0.1 0.25 
         Note: * repeated the process for sample size 𝑁 = 250, 500,1000. 
 
Analysis: Estimating risk difference 
RD was estimated for each simulated dataset using three IV-based approaches. The 
measured confounder 𝑋 was adjusted for at each stage. In the dataset generation procedure, the 
outcome was linear with the log transformed 𝑋.In real data analysis, however, we would not know 
the exact functional relationship between the covariate and outcome. Therefore, in the data analysis 
step, we used restricted cubic splines to flexibly model the functional form of the covariate. The 
“rcs” function from R package “rms” was used to do this. Additionally, we estimated the CACE 
with the 2SLS method without adjusting for the measured confounder. Robust standard error (R 
packages “sandwich” and “lmtest” were applied, type= “HC4”) was required in the last stage of 
each method.  
As with the previous simulation section, we report the bias, relative bias, average of 
standard error (ASE), empirical standard error (ESE), coverage probability (CP), and power in 




Overall, after adjusting for the measured confounder, the statistical properties of these three 
methods are not identical unlike the simulation results from the previous section. This is 
particularly evident when the sample size is small and compliance probability is low.  
In terms of relative bias (Figure14), we can see that the 3-stage model generated the 
smallest relative bias when the sample size was small, for example, when N=100, compliance 
probability was low, relative risk at 0.15, the relative risk from 3 stage model was as low as 0.004, 
while 2SLS was 0.03, and LG-LM was as high as 0.09. As the sample size increases, the difference 
becomes negligible. Also, the difference between 2SLS and 3 stage model is trivial when the 
compliance probability is high regardless of the sample size. Although the relative bias from LG-
LM approach can decrease to as low as 1.5% when the sample size increase to 1000, the relative 
bias is consistently higher than other methods, especially when the sample size is small.  
Similar trends were observed in terms of efficiency (Figure 15) and power (Figure 16). 
When the sample size was as small as 100 and compliance was low, the standard errors from the 
3-stage approach were considerably smaller than those from 2SLS. As the sample size increased, 
the difference became negligible. For power, the 3-stage approach has stronger power than the 
2SLS when the sample size is small. However, when the compliance was high, the behavior of 
these three methods were similar in terms of efficiency and power regardless of sample size. 
Therefore, when the sample size and the compliance probability are both small, the 3-stage method 
outperforms the other two methods. 
In contrast, the three methods displayed almost the same performance in terms of CP 
(Figure 17). The CP in all cases were around 95%.  
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Finally, for the 2SLS approach, accounting for the measured confounder did not show any 
improved efficiency or decreased relative bias. Its performance is nearly the same as the 2SLS 
approach without covariate adjustment.   
In sum, adjusting for the measured confounder, the 3-stage method performs better than 
the other three methods, especially when the sample size is small. The LG-LM method is likely to 
generate substantially higher relative bias than the other three methods when the sample size is 
small.  
 




Figure 15. ESE of IV-based methods in each scenario 
 
 




Figure 17. CP of each scenario using IV-based methods 
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4.0  DISCUSSION AND CONCLUSION 
In RCTs, non-compliance to the assigned treatment often threaten the validity of estimation 
of treatment efficacy. CACE has been known as a potential estimate to represent the average 
treatment effects in the subgroup of compliers. IV-based method have been proposed to provide 
valid estimate of CACE. Although there have been many research investigated the IV-based 
methods in estimating CACE for binary outcome and binary treatment groups, most of them 
focused on estimating risk ratios or odds ratios. In this study, we studied the effectiveness of IV-
based methods for the estimation of risk difference in RCTs with non-compliance, when both the 
exposure and outcome are binary. We conducted a series of simulation studies to compare three 
IV-based methods and conventional method PP with respect to bias, efficiency, CP and power in 
estimating risk difference as the CACE. We also examined how their performance is affected by 
varying levels of compliance, effect size, and sample size. In addition, we evaluated the behavior 
of three IV methods when measured confounders exist.  
The results from all simulations indicate that compliance probability is a critical factor that 
influences the performance of different methods. For example, when the compliance probability 
is high, such as 0.95, each method tends to give valid estimate of treatment efficacy, although the 
relative bias from the PP method is consistently higher than IV methods. However, as the 
compliance at low or median level, the estimation obtained from PP method is highly biased, while 
the three IV-based methods still provide unbiased estimate.   
Also, we examined the performance of the three IV-based methods in different levels of 
compliance, risk difference, and sample size, when there is no measured confounders. We found 
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that all the IV-based methods generally provide valid and almost the same estimates, efficiency 
and power in the setting of no measured confounders.  
However, when measured confounders exist and we account for them, the 3-stage method 
performs better than the other two methods, especially when the sample size is small. It provides 
more efficient estimates and yield higher power. In contrast, the LG-LM method is likely to 
generate substantially higher relative bias than the other two methods when the sample size is 
small. However, as the compliance probability goes to 1 or as the sample size increases, the 
differences between the different IV-based methods become negligible. 
When the research interest is in estimating the risk difference and there is no measured 
confounder, we mathematically and empirically showed that 2SLS is a valid approach to estimate 
CACE in the setting of binary outcome and treatment groups. We recommend using 2SLS to 
estimate when there is no measured confounder, as 2SLS is easier to perform and it will generate 
consistent estimate even when the model is misspecified. However, when there is measured 
confounder and the sample size is relatively small, we suggest using the 3-stage approach, as it 
will generate more efficient estimate and provide higher power. On the other hand, we would not 
suggest the use of LG-LM method, as it will give rise to estimates with high relative bias. The 
reason could be when the first stage is logistic regression, and the model is misspecified, unlike 
the 2SLS approach, it will not generate consistent estimate. However, when there is no measured 
confounders and treatment assignment is the only predictor in the first stage, fitting linear 
regression or logistic regression in the first stage will not cause inconsistency, as long as the 
probability is not extremely high or low[39].    
In the last simulation, we did not observe significant improvement of efficiency when 
including measured confounder in the 2SLS compared to the estimate from 2SLS without adjusting 
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for a measured confounder. The potential reason could be including one confounder in the 
simulation model may not be sufficient to change the performance of 2SLS. In a future study, 
additional covariates could be included in the diagram to explore the influence of measured 
confounders on the performance of 2SLS method.   
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APPENDIX A: RESULT TABLES 
Table 4. Relative bias and power of each scenario using four methods (Figure 5 and 6) 
SCENARI
O 

















1 N/A 0.0490 N/A 0.0490 N/A 0.0490 N/A 0.1590 
2 0.0066 0.5280 0.0066 0.5170 0.0066 0.5170 0.3092 0.9670 
3 0.0086 0.9720 0.0086 0.9670 0.0086 0.9670 0.1583 1.0000 
4 N/A 0.0480 N/A 0.0490 N/A 0.0490 N/A 0.0490 
5 -0.0100 0.8110 -0.0100 0.8080 -0.0100 0.8080 0.0722 0.9390 
6 -0.0046 1.0000 -0.0046 1.0000 -0.0046 1.0000 0.0390 1.0000 
 
 
Table 5. ESE and ASE of each scenario using four methods (Figure 7) 
SCENARIO 2SLS LG-LM 3SLS PP 
ASE ESE ASE ESE ASE ESE ASE ESE 
1 0.0749 0.0739 0.0747 0.0739 0.0747 0.0739 0.0497 0.0505 
2 0.0763 0.0748 0.0772 0.0748 0.0772 0.0748 0.0515 0.0515 
3 0.0751 0.0753 0.0782 0.0753 0.0782 0.0753 0.0499 0.0513 
4 0.0513 0.0502 0.0513 0.0502 0.0513 0.0502 0.0437 0.0426 
5 0.0530 0.0525 0.0534 0.0525 0.0534 0.0525 0.0456 0.0453 
6 0.0524 0.0538 0.0536 0.0538 0.0536 0.0538 0.0450 0.0459 
 
 
Table 6. CP of each scenario using four methods (Figure 8) 
SCENARIO 2SLS LG-LM 3SLS PP 
CP CP CP CP 
1 0.9510 0.9510 0.9510 0.8480 
2 0.9640 0.9660 0.9660 0.8450 
3 0.9520 0.9560 0.9560 0.8250 
4 0.9520 0.9510 0.9510 0.9510 
5 0.9460 0.9460 0.9460 0.9430 







Table 7. Relative bias and power of each scenario using IV-based methods (Figure 9 and 11) 








1 N/A* 0.055 N/A 0.063 N/A 0.063 
2 -0.0226 0.038 -0.0226 0.044 -0.0226 0.044 
3 0.0887 0.074 0.0887 0.078 0.0887 0.078 
4 -0.0531 0.113 -0.0531 0.119 -0.0531 0.119 
5 0.0140 0.180 0.0140 0.183 0.0140 0.183 
6 -0.0160 0.236 -0.0160 0.230 -0.0160 0.230 
7 N/A 0.046 N/A 0.050 N/A 0.050 
8 -0.0592 0.063 -0.0592 0.068 -0.0592 0.068 
9 0.0549 0.112 0.0549 0.115 0.0549 0.115 
10 0.0486 0.185 0.0486 0.181 0.0486 0.181 
11 0.0128 0.272 0.0128 0.260 0.0128 0.260 
12 0.0312 0.410 0.0312 0.399 0.0312 0.399 
13 N/A 0.067 N/A 0.068 N/A 0.068 
14 0.0467 0.055 0.0467 0.057 0.0467 0.057 
15 -0.0414 0.135 -0.0414 0.135 -0.0414 0.135 
16 -0.0083 0.238 -0.0083 0.229 -0.0083 0.229 
17 0.0141 0.376 0.0141 0.369 0.0141 0.369 
18 0.0047 0.535 0.0047 0.529 0.0047 0.529 
19 N/A 0.055 N/A 0.053 N/A 0.053 
20 0.0557 0.092 0.0557 0.088 0.0557 0.088 
21 0.0302 0.183 0.0302 0.178 0.0302 0.178 
22 -0.0051 0.301 -0.0051 0.295 -0.0051 0.295 
23 0.0116 0.529 0.0116 0.520 0.0116 0.520 
24 -0.0049 0.693 -0.0049 0.687 -0.0049 0.687 
25 N/A 0.046 N/A 0.049 N/A 0.049 
26 0.0180 0.074 0.0180 0.077 0.0180 0.077 
27 0.0121 0.136 0.0121 0.135 0.0121 0.135 
28 0.0244 0.230 0.0244 0.229 0.0244 0.229 
29 -0.0219 0.345 -0.0219 0.331 -0.0219 0.331 
30 0.0403 0.544 0.0403 0.535 0.0403 0.535 
31 N/A 0.046 N/A 0.046 N/A 0.046 
32 0.0847 0.086 0.0847 0.085 0.0847 0.085 
33 -0.0462 0.153 -0.0462 0.150 -0.0462 0.150 
34 0.0255 0.360 0.0255 0.354 0.0255 0.354 
35 -0.0061 0.541 -0.0061 0.529 -0.0061 0.529 
36 -0.0136 0.755 -0.0136 0.747 -0.0136 0.747 
37 N/A 0.046 N/A 0.045 N/A 0.045 
38 0.0375 0.120 0.0375 0.119 0.0375 0.119 
39 0.0358 0.275 0.0358 0.275 0.0358 0.275 
40 -0.0079 0.464 -0.0079 0.458 -0.0079 0.458 
41 0.0162 0.749 0.0162 0.744 0.0162 0.744 
42 0.0058 0.918 0.0058 0.917 0.0058 0.917 
43 N/A 0.058 N/A 0.058 N/A 0.058 
44 0.0421 0.130 0.0421 0.131 0.0421 0.131 
45 -0.0130 0.328 -0.0130 0.323 -0.0130 0.323 
46 0.0147 0.638 0.0147 0.633 0.0147 0.633 
47 0.0035 0.881 0.0035 0.881 0.0035 0.881 
48 0.0039 0.973 0.0039 0.973 0.0039 0.973 
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49 N/A 0.043 N/A 0.045 N/A 0.045 
50 -0.0015 0.089 -0.0015 0.088 -0.0015 0.088 
51 0.0052 0.200 0.0052 0.198 0.0052 0.198 
52 -0.0344 0.380 -0.0344 0.374 -0.0344 0.374 
53 0.0075 0.650 0.0075 0.638 0.0075 0.638 
54 0.0050 0.811 0.0050 0.805 0.0050 0.805 
55 N/A 0.053 N/A 0.056 N/A 0.056 
56 -0.0182 0.114 -0.0182 0.112 -0.0182 0.112 
57 0.0053 0.314 0.0053 0.311 0.0053 0.311 
58 0.0132 0.609 0.0132 0.605 0.0132 0.605 
59 0.0052 0.848 0.0052 0.842 0.0052 0.842 
60 0.0076 0.968 0.0076 0.963 0.0076 0.963 
61 N/A 0.052 N/A 0.052 N/A 0.052 
62 0.0354 0.152 0.0354 0.152 0.0354 0.152 
63 -0.0041 0.427 -0.0041 0.427 -0.0041 0.427 
64 -0.0083 0.757 -0.0083 0.754 -0.0083 0.754 
65 0.0107 0.967 0.0107 0.964 0.0107 0.964 
66 -0.0165 1.000 -0.0165 0.999 -0.0165 0.999 
67 N/A 0.048 N/A 0.047 N/A 0.047 
68 0.0158 0.201 0.0158 0.201 0.0158 0.201 
69 0.0051 0.593 0.0051 0.591 0.0051 0.591 
70 0.0104 0.897 0.0104 0.894 0.0104 0.894 
71 -0.0012 0.990 -0.0012 0.990 -0.0012 0.990 




Table 8. ESE and ASE of each scenario using IV-based methods (Figure 10) 
SCENARIO 2SLS LG-LM 3SLS 
ASE ESE ASE ESE ASE ESE 
1 0.2049 0.2143 0.2048 0.2143 0.2048 0.2143 
2 0.2061 0.1999 0.2062 0.1999 0.2062 0.1999 
3 0.2039 0.2038 0.2042 0.2038 0.2042 0.2038 
4 0.2022 0.2055 0.2033 0.2055 0.2033 0.2055 
5 0.2016 0.2081 0.2031 0.2081 0.2031 0.2081 
6 0.1995 0.2041 0.2024 0.2041 0.2024 0.2041 
7 0.1548 0.1507 0.1556 0.1507 0.1556 0.1507 
8 0.1554 0.1596 0.1561 0.1596 0.1561 0.1596 
9 0.1545 0.1593 0.1555 0.1593 0.1555 0.1593 
10 0.1528 0.1541 0.1543 0.1541 0.1543 0.1541 
11 0.1517 0.1530 0.1537 0.1530 0.1537 0.1530 
12 0.1490 0.1539 0.1516 0.1539 0.1516 0.1539 
13 0.1251 0.1321 0.1260 0.1321 0.1260 0.1321 
14 0.1251 0.1236 0.1261 0.1236 0.1261 0.1236 
15 0.1242 0.1259 0.1253 0.1259 0.1253 0.1259 
16 0.1228 0.1239 0.1243 0.1239 0.1243 0.1239 
17 0.1210 0.1276 0.1226 0.1276 0.1226 0.1276 
18 0.1197 0.1252 0.1218 0.1252 0.1218 0.1252 
19 0.1050 0.1056 0.1060 0.1056 0.1060 0.1056 
20 0.1043 0.1088 0.1053 0.1088 0.1053 0.1088 
21 0.1036 0.1061 0.1047 0.1061 0.1047 0.1061 
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22 0.1030 0.1039 0.1041 0.1039 0.1041 0.1039 
23 0.1007 0.0992 0.1019 0.0992 0.1019 0.0992 
24 0.0985 0.1019 0.0998 0.1019 0.0998 0.1019 
25 0.1286 0.1289 0.1285 0.1289 0.1285 0.1289 
26 0.1274 0.1313 0.1275 0.1313 0.1275 0.1313 
27 0.1270 0.1352 0.1272 0.1352 0.1272 0.1352 
28 0.1261 0.1252 0.1268 0.1252 0.1268 0.1252 
29 0.1257 0.1275 0.1269 0.1275 0.1269 0.1275 
30 0.1241 0.1246 0.1260 0.1246 0.1260 0.1246 
31 0.0974 0.0974 0.0976 0.0974 0.0976 0.0974 
32 0.0977 0.0948 0.0980 0.0948 0.0980 0.0948 
33 0.0965 0.0946 0.0969 0.0946 0.0969 0.0946 
34 0.0962 0.0915 0.0968 0.0915 0.0968 0.0915 
35 0.0952 0.0960 0.0963 0.0960 0.0963 0.0960 
36 0.0939 0.0914 0.0954 0.0914 0.0954 0.0914 
37 0.0791 0.0792 0.0794 0.0792 0.0794 0.0792 
38 0.0789 0.0825 0.0791 0.0825 0.0791 0.0825 
39 0.0786 0.0833 0.0790 0.0833 0.0790 0.0833 
40 0.0776 0.0766 0.0782 0.0766 0.0782 0.0766 
41 0.0763 0.0773 0.0771 0.0773 0.0771 0.0773 
42 0.0751 0.0741 0.0762 0.0741 0.0762 0.0741 
43 0.0664 0.0681 0.0667 0.0681 0.0667 0.0681 
44 0.0663 0.0647 0.0666 0.0647 0.0666 0.0647 
45 0.0658 0.0665 0.0661 0.0665 0.0661 0.0665 
46 0.0649 0.0652 0.0652 0.0652 0.0652 0.0652 
47 0.0639 0.0631 0.0642 0.0631 0.0642 0.0631 
48 0.0624 0.0619 0.0629 0.0619 0.0629 0.0619 
49 0.0898 0.0883 0.0898 0.0883 0.0898 0.0883 
50 0.0897 0.0889 0.0897 0.0889 0.0897 0.0889 
51 0.0894 0.0899 0.0897 0.0899 0.0897 0.0899 
52 0.0887 0.0896 0.0892 0.0896 0.0892 0.0896 
53 0.0882 0.0872 0.0891 0.0872 0.0891 0.0872 
54 0.0871 0.0905 0.0885 0.0905 0.0885 0.0905 
55 0.0688 0.0677 0.0688 0.0677 0.0688 0.0677 
56 0.0687 0.0699 0.0688 0.0699 0.0688 0.0699 
57 0.0685 0.0684 0.0687 0.0684 0.0687 0.0684 
58 0.0679 0.0703 0.0683 0.0703 0.0683 0.0703 
59 0.0673 0.0661 0.0680 0.0661 0.0680 0.0661 
60 0.0664 0.0666 0.0674 0.0666 0.0674 0.0666 
61 0.0559 0.0562 0.0560 0.0562 0.0560 0.0562 
62 0.0559 0.0557 0.0560 0.0557 0.0560 0.0557 
63 0.0554 0.0548 0.0556 0.0548 0.0556 0.0548 
64 0.0549 0.0580 0.0552 0.0580 0.0552 0.0580 
65 0.0541 0.0538 0.0546 0.0538 0.0546 0.0538 
66 0.0531 0.0533 0.0538 0.0533 0.0538 0.0533 
67 0.0470 0.0471 0.0471 0.0471 0.0471 0.0471 
68 0.0469 0.0473 0.0470 0.0473 0.0470 0.0473 
69 0.0466 0.0470 0.0467 0.0470 0.0467 0.0470 
70 0.0459 0.0470 0.0461 0.0470 0.0461 0.0470 
71 0.0452 0.0445 0.0454 0.0445 0.0454 0.0445 
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Table 9. CP of each scenario using IV-based methods (Figure 12) 
SCENARIO 2SLS LG-LM 3SLS 
CP CP CP 
1 0.943 0.936 0.936 
2 0.964 0.959 0.959 
3 0.958 0.946 0.946 
4 0.960 0.957 0.957 
5 0.949 0.944 0.944 
6 0.944 0.941 0.941 
7 0.953 0.950 0.950 
8 0.949 0.948 0.948 
9 0.941 0.939 0.939 
10 0.953 0.948 0.948 
11 0.940 0.939 0.939 
12 0.936 0.936 0.936 
13 0.929 0.930 0.930 
14 0.956 0.956 0.956 
15 0.947 0.948 0.948 
16 0.947 0.944 0.944 
17 0.933 0.940 0.940 
18 0.939 0.943 0.943 
19 0.944 0.945 0.945 
20 0.937 0.942 0.942 
21 0.948 0.952 0.952 
22 0.933 0.936 0.936 
23 0.947 0.948 0.948 
24 0.936 0.944 0.944 
25 0.953 0.950 0.950 
26 0.946 0.943 0.943 
27 0.937 0.931 0.931 
28 0.955 0.956 0.956 
29 0.953 0.949 0.949 
30 0.958 0.957 0.957 
31 0.954 0.952 0.952 
32 0.958 0.959 0.959 
33 0.956 0.955 0.955 
34 0.963 0.963 0.963 
35 0.946 0.948 0.948 
36 0.958 0.963 0.963 
37 0.954 0.954 0.954 
38 0.946 0.946 0.946 
39 0.939 0.940 0.940 
40 0.944 0.944 0.944 
41 0.937 0.940 0.940 
42 0.951 0.956 0.956 
43 0.941 0.941 0.941 
44 0.961 0.961 0.961 
45 0.951 0.949 0.949 
46 0.948 0.948 0.948 
47 0.944 0.944 0.944 
48 0.950 0.952 0.952 
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49 0.957 0.954 0.954 
50 0.954 0.953 0.953 
51 0.954 0.954 0.954 
52 0.950 0.950 0.950 
53 0.959 0.959 0.959 
54 0.939 0.942 0.942 
55 0.945 0.943 0.943 
56 0.956 0.955 0.955 
57 0.957 0.957 0.957 
58 0.943 0.945 0.945 
59 0.953 0.955 0.955 
60 0.948 0.952 0.952 
61 0.948 0.948 0.948 
62 0.948 0.948 0.948 
63 0.956 0.956 0.956 
64 0.940 0.943 0.943 
65 0.955 0.955 0.955 
66 0.951 0.952 0.952 
67 0.952 0.952 0.952 
68 0.949 0.950 0.950 
69 0.947 0.947 0.947 
70 0.941 0.942 0.942 
71 0.954 0.954 0.954 
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Table 10. relative bias and power of each scenario using IV-based methods (Figure 14 and 16) 
SCENARI
O 

















1 N/A 0.0400 N/A 0.0380 N/A 0.0440 N/A 0.0440 
2 0.0331 0.1330 0.0354 0.1300 0.0892 0.1550 0.0044 0.1550 
3 0.0126 0.3930 0.0046 0.3880 0.0948 0.4800 0.0027 0.4800 
4 N/A 0.0590 N/A 0.0560 N/A 0.0580 N/A 0.0580 
5 -0.0007 0.2760 -0.0043 0.2690 0.0605 0.2710 -0.0102 0.2710 
6 0.0158 0.8270 0.0161 0.8120 0.0844 0.8180 0.0137 0.8180 
7 N/A 0.0450 N/A 0.0510 N/A 0.0530 N/A 0.0530 
8 0.0044 0.2500 -0.0028 0.2650 0.0229 0.3380 -0.0035 0.3380 
9 0.0021 0.7700 0.0032 0.7700 0.0322 0.8700 0.0062 0.8700 
10 N/A 0.0430 N/A 0.0390 N/A 0.0420 N/A 0.0420 
11 0.0229 0.6130 0.0257 0.6120 0.0519 0.6200 0.0247 0.6200 
12 0.0039 0.9980 0.0030 0.9970 0.0287 0.9980 0.0022 0.9980 
13 N/A 0.0480 N/A 0.0490 N/A 0.0520 N/A 0.0520 
14 0.0174 0.4760 0.0118 0.4740 0.0109 0.5580 -0.0003 0.5580 
15 0.0003 0.9620 -0.0010 0.9610 0.0171 0.9900 0.0057 0.9900 
16 N/A 0.0460 N/A 0.0500 N/A 0.0530 N/A 0.0530 
17 0.0190 0.8890 0.0184 0.8930 0.0296 0.8890 0.0170 0.8890 
18 0.0012 1.0000 -0.0004 1.0000 0.0112 1.0000 -0.0012 1.0000 
19 N/A 0.0460 N/A 0.0530 N/A 0.0520 N/A 0.0520 
20 0.0088 0.7560 0.0083 0.7720 0.0093 0.8640 0.0040 0.8640 
21 -0.0071 1.0000 -0.0072 1.0000 0.0010 1.0000 -0.0044 1.0000 
22 N/A 0.0420 N/A 0.0430 N/A 0.0420 N/A 0.0420 
23 0.0076 0.9930 0.0073 0.9930 0.0123 0.9930 0.0063 0.9930 















Table 11. ESE and ASE of each scenario using IV-based methods (Figure 15) 
SCENARIO LM-LM LM-LM-X LG-LM-X LG-LM-LM-X 
ASE ESE ASE  ESE ASE ESE ASE ESE 
1 0.1850 0.1855 0.1864 0.1886 0.1726 0.1717 0.1588 0.1583 
2 0.1849 0.1878 0.1864 0.1900 0.1738 0.1748 0.1598 0.1618 
3 0.1811 0.1782 0.1822 0.1743 0.1709 0.1670 0.1568 0.1492 
4 0.1105 0.1118 0.1118 0.1127 0.1175 0.1183 0.1099 0.1107 
5 0.1098 0.1111 0.1114 0.1122 0.1175 0.1192 0.1098 0.1106 
6 0.1042 0.1034 0.1052 0.1051 0.1113 0.1119 0.1040 0.1044 
7 0.1147 0.1141 0.1142 0.1138 0.1009 0.0989 0.0983 0.0964 
8 0.1150 0.1128 0.1144 0.1127 0.1019 0.1051 0.0993 0.1023 
9 0.1124 0.1121 0.1117 0.1111 0.0998 0.0996 0.0973 0.0966 
10 0.0694 0.0667 0.0693 0.0659 0.0702 0.0669 0.0684 0.0652 
11 0.0690 0.0690 0.0688 0.0681 0.0699 0.0689 0.0681 0.0669 
12 0.0656 0.0667 0.0654 0.0662 0.0667 0.0672 0.0649 0.0656 
13 0.0805 0.0813 0.0797 0.0806 0.0696 0.0708 0.0688 0.0700 
14 0.0809 0.0818 0.0802 0.0812 0.0706 0.0729 0.0698 0.0721 
15 0.0789 0.0764 0.0782 0.0763 0.0692 0.0666 0.0684 0.0657 
16 0.0491 0.0501 0.0487 0.0497 0.0487 0.0499 0.0481 0.0493 
17 0.0487 0.0471 0.0484 0.0465 0.0485 0.0470 0.0479 0.0464 
18 0.0463 0.0466 0.0459 0.0461 0.0463 0.0463 0.0457 0.0458 
19 0.0566 0.0575 0.0560 0.0572 0.0488 0.0495 0.0485 0.0492 
20 0.0569 0.0559 0.0563 0.0550 0.0495 0.0490 0.0492 0.0488 
21 0.0556 0.0543 0.0551 0.0535 0.0485 0.0461 0.0483 0.0458 
22 0.0347 0.0337 0.0343 0.0333 0.0342 0.0331 0.0340 0.0329 
23 0.0344 0.0352 0.0341 0.0346 0.0340 0.0345 0.0338 0.0343 














Table 12. CP of each scenario using IV-based methods (Figure 17) 
SCENARIO LM-LM LM-LM-X LG-LM-X LG-LM-LM-X 
CP CP CP CP 
1 0.9600 0.9620 0.9560 0.9560 
2 0.9540 0.9430 0.9340 0.9370 
3 0.9590 0.9610 0.9560 0.9610 
4 0.9410 0.9440 0.9420 0.9420 
5 0.9440 0.9450 0.9420 0.9440 
6 0.9440 0.9470 0.9310 0.9460 
7 0.9550 0.9490 0.9470 0.9470 
8 0.9590 0.9550 0.9360 0.9370 
9 0.9520 0.9540 0.9390 0.9400 
10 0.9570 0.9610 0.9580 0.9580 
11 0.9500 0.9520 0.9500 0.9460 
12 0.9530 0.9480 0.9530 0.9590 
13 0.9520 0.9510 0.9480 0.9480 
14 0.9550 0.9540 0.9450 0.9450 
15 0.9560 0.9470 0.9580 0.9620 
16 0.9540 0.9500 0.9470 0.9470 
17 0.9590 0.9620 0.9560 0.9560 
18 0.9460 0.9530 0.9510 0.9530 
19 0.9540 0.9470 0.9480 0.9480 
20 0.9500 0.9540 0.9550 0.9560 
21 0.9630 0.9550 0.9660 0.9660 
22 0.9580 0.9570 0.9580 0.9580 
23 0.9550 0.9540 0.9550 0.9570 












APPENDIX B: R SAMPLE CODES 
## n: sample size, Pc: comply% given treat=1, b0=0, b1: treatment effect, 
## P0: binary outcome baseline mean P=0.5 
######################## Parameters########################### 
## generate all kinds of combination 
risk <- c(0.00, 0.05, 0.1, 0.15, 0.2, 0.25) 
comply.per <- c(0.5, 0.65, 0.8, 0.95) 
size<- c(100, 250, 500) 
combination <- function(n,Pc,b1){ 
        x <- matrix(0,nrow = 24, ncol = 3) 
        for(j in 1:length(Pc)){ 
                for (k in 1:length(b1)){ 
                        x[(k+6*(j-1)),]<- c(n,Pc[j],b1[k]) 
                } 
        } 
        return(x)         
} 
size.100 <- combination(size[1],comply.per,risk) 
size.250 <- combination(size[2],comply.per,risk) 
size.500 <- combination(size[3],comply.per,risk) 
all.combi <- rbind(size.100, size.250, size.500) 
new.combi<- data.frame(cbind(all.combi[,c(1,2)],all.combi[,3],0.5))   ## 
generate all kinds of combination 
names(new.combi)<-c("size","Pcomply","effect","P0") 
write.csv(new.combi,file = 'parameters set_binary.csv') 
 
###########################dataset generation######################## 
data.gen_bi <- function(n,Pc,b1,P0){ 
        gen_data <- list() 
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        trails <- 1000 
        for (i in 1:trails) { 
                # generate treatment assignment 
                treat <- rbinom(n, 1, 0.5)  ## n sample size 
                # order treat 
                data.1 <- cbind(treat) 
                data.1 <- data.1[order(-treat),]############ order by treat 
                n.treat <- table(treat)    
                # n.treat[2] is the number that treat=1 
                # compliance: 0.5, generate comply 
                comply <- rbinom(n.treat[2], 1, Pc)   
                # generate comply status given treat=1 
                rest <- rep(0, n.treat[1])    
               # generate comply status=0 given treat=0 
                comply <- c(comply,rest)     # merge comply and rest 
                data.1 <- cbind(data.1,comply)  
                ## binary outcome, set baseline p=0.5,  
                ##means if subjects do not comply, their chance of event is 0.5 
                ## treatment effect b1  
                data.1 <- data.frame(data.1[order(comply),])  
               # order by comply, increasing  
               # generate binary outcome when comply=0 , p=0.5 
               binary.y.0 <-rbinom(length(data.1[data.1$comply==0,2]),1,P0) 
               set.seed(s_4*trails+i) 
               binary.y.1<-rbinom(length(data.1[data.1$comply==1,2]),1,P0+b1) 
               binary.y <- c(binary.y.0,binary.y.1)  
               data.1<- data.frame(cbind(data.1,binary.y)) 
               names(data.1) <- c("treat","comply","binary.y")  
               gen_data[[i]] <- data.1  
        } 
         




data1_72 <- function(x){ 
        new.data <- list() 
        for (i in 1:72){ 
                new.data[[i]] <-
data.gen_bi(x[i,1],x[i,2],x[i,3],x[i,4],x[i,5], 
                                         x[i,6],x[i,7],x[i,8]) 
              } 
        return(new.data) 
} 
Set.seed(1567) 
all.data_bi <- data1_72(new.combi) 










present.2SLS.bi <- function(all.data,parameter){ 
        Bias <- c() 
        ASE <- c() 
        ESE <- c() 
        CP <- c() 
        median_est <- c()  # output the median of point estimate 
        relative_bias <- c()  
        #calculate the relative bias, relative_bias=mean(bias)/effect 
        power_bi <- c()  #calcualte the power 
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        for (i in 1:72) { 
                est.bi <- c()    #point estimate 
                est.bi.se <- c()   #Robust SE for point estimate 
                lower.bi <- c()    # lower 95% CI 
                upper.bi <- c()    # upper 95% CI 
                bias.bi <- c()         # bias for each point estimate 
                converge.p.bi <- c()    
                # converge symbol: 1, true treatment effect falls in 95% CI 
                p_value <- c()  # extract the p value for each treatment term 
                pow <- c()    
               # power indicator: equals if the p value of  
               #treatment term smaller than 0.05 
                 
                for (j in 1:1000){ 
                        data_1 <- all.data[[i]][[j]] 
                        # define outcome, instrument, endogenous variable 
                        Y1 <- data_1$binary.y 
                        Y2 <- data_1$comply 
                        X2 <- data_1$treat 
                        # 2SLS estimation (AER Package) 
                        ivreg.bi <- ivreg(Y1 ~ Y2|X2)  
                         
                        # sandwich_se <- diag(vcovHC(mod, type = "HC"))^0.5 
                        # temp.1 <- summary(ivreg.bi, vcov=sandwich) 
                        temp.1 <- coeftest(ivreg.bi, vcov=vcovHC(ivreg.bi, 
type = "HC4")) 
                        est.bi[j] <- temp.1[2,1] 
                         
                        est.bi.se[j] <- temp.1[2,2] 
                        p_value[j] <- temp.1[2,4] 
                        pow[j] <- ifelse(p_value[j]<0.05, 1, 0)  
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                       ## if the treatment coefficient=0 was rejected, 
                       ## then symbol as 1 
                         
                         
                        lower.bi[j] <-coefci(ivreg.bi, vcov=vcovHC(ivreg.bi, 
type = "HC4"))[2,1]  ## calculate CI based on robust SE 
                        upper.bi[j] <-coefci(ivreg.bi, vcov=vcovHC(ivreg.bi, 
type = "HC4"))[2,2] 
                         
                        converge.p.bi[j] <- ifelse(parameter[i,3]>lower.bi[j] 
& parameter[i,3]<upper.bi[j], 1, 0) 
                        bias.bi[j] <-est.bi[j]-parameter[i,3]  
                } 
                Bias[i] <- mean(bias.bi) 
                ASE[i] <- mean(est.bi.se) 
                ESE[i] <- sd(est.bi) 
                CP[i] <- sum(converge.p.bi)/1000 
                power_bi[i] <- sum(pow)/1000 
                median_est[i] <- median(est.bi) 
                relative_bias[i] <- mean(bias.bi)/(parameter[i,3]) 
        } 
        return(cbind(Bias,ASE,ESE,CP,power_bi,median_est,relative_bias)) 
        
} 
LM_LM_Bi <- data.frame(present.2SLS.bi(all.data_bi,new.combi)) 
write.csv(LM_LM_Bi, file="lm_lm_bi.csv") 
####################################################################### 
## approach 2: lg_lm 
present.lg_lm.bi<- function(all.data,parameter){ 
  Bias <- c() 
  ASE <- c() 
  ESE <- c() 
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  CP <- c() 
  median_est <- c()  # output the median of point estimate 
  relative_bias <- c() 
  #calculate the relative bias, relative_bias= mean(bias)/effect 
  power_bi <- c()  #calcualte the power 
  for (i in 1:72) { 
    est.bi <- c()    #point estimate 
    est.bi.se <- c()   #Robust SE for point estimate 
    lower.bi <- c()    # lower 95% CI 
    upper.bi <- c()    # upper 95% CI 
    bias.bi <- c()         # bias for each point estimate 
converge.p.bi <- c()    
# converge symbol: 1, true treatment effect falls in 95% CI 
    p_value <- c()  # extract the p value for each treatment term 
pow <- c()    
   # power indicator: equals if the p value of treatment term smaller than 0.05 
    for (j in 1:1000){ 
      data_1 <- all.data[[i]][[j]] 
      # define outcome, instrument, endogenous variable 
      Y1 <- data_1$binary.y 
      Y2 <- data_1$comply 
      X2 <- data_1$treat 
      # 1st stage fit logistic regression 
      logisreg.bi <- glm(Y2~X2,family = binomial(link ='logit'), data =data_1, 
                         control = list(maxit = 50)) 
      phat.bi<- predict(logisreg.bi, type="response") 
  
      # 2nd stage fit linear regression estimate treatment effect 
      logi.bi <- lm(Y1 ~ phat.bi) 
       
      temp.2 <- coeftest(logi.bi, vcov=vcovHC(logi.bi, type = "HC4")) 
      est.bi[j] <- temp.2[2,1]  
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      est.bi.se[j] <- temp.2[2,2] 
      p_value[j] <- temp.2[2,4] 
      pow[j] <- ifelse(p_value[j]<0.05, 1, 0)   
      ## if the treatment coefficient=0 was rejected, then symbol as 1  
      lower.bi[j] <-coefci(logi.bi, vcov=vcovHC(logi.bi, type = "HC4"))[2,1]             
## calculate CI based on robust SE 
      upper.bi[j] <-coefci(logi.bi, vcov=vcovHC(logi.bi, type = "HC4"))[2,2]  
      converge.p.bi[j] <- ifelse(parameter[i,3]>lower.bi[j] & 
parameter[i,3]<upper.bi[j], 1, 0) 
      bias.bi[j] <-est.bi[j]-parameter[i,3]  
    } 
    Bias[i] <- mean(bias.bi) 
    ASE[i] <- mean(est.bi.se) 
    ESE[i] <- sd(est.bi) 
    CP[i] <- sum(converge.p.bi)/1000 
    power_bi[i] <- sum(pow)/1000 
    median_est[i] <- median(est.bi) 
    relative_bias[i] <- mean(bias.bi)/(parameter[i,3]) 
  } 
  return(cbind(Bias,ASE,ESE,CP,power_bi,median_est,relative_bias))  
} 
LG_LM_Bi <- data.frame(present.lg_lm.bi(all.data_bi,new.combi)) 
write.csv(LG_LM_Bi, file="lg_lm_bi.csv") 
####################################################################### 
## approach 3:  3 stage least square 
present.lg_lm_lm.bi<- function(all.data,parameter){ 
        Bias <- c() 
        ASE <- c() 
        ESE <- c() 
        CP <- c() 
        median_est <- c()  # output the median of point estimate 
        relative_bias <- c()  
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        #calculate the relative bias, relative_bias=mean(bias)/effect 
        power_bi <- c()  #calcualte the power 
        for (i in 1:72) { 
                est.bi <- c()    #point estimate 
                est.bi.se <- c()   #Robust SE for point estimate 
                lower.bi <- c()    # lower 95% CI 
                upper.bi <- c()    # upper 95% CI 
                bias.bi <- c()         # bias for each point estimate 
                converge.p.bi <- c()    
          # converge symbol: 1, true treatment effect falls in 95% CI 
                p_value <- c()  # extract the p value for each treatment term 
                pow <- c()    
   # power indicator: equals if the p value of treatment term smaller than 0.05 
                for (j in 1:1000){ 
                        data_1 <- all.data[[i]][[j]] 
                        # define outcome, instrument, endogenous variable 
                        Y1 <- data_1$binary.y 
                        Y2 <- data_1$comply 
                        X2 <- data_1$treat  
                        # 1st stage fit logistic regression 
                        logisreg.bi <- glm(Y2~X2,family = binomial(link 
='logit'), data =data_1, 
                                           control = list(maxit = 50)) 
                        phat.bi<- predict(logisreg.bi, type="response")  
                        # 2nd stage linear regression Y2 on X2 hat 
                        lg_lm_lm.bi_2 <- lm(Y2~phat.bi) 
                        Y2_hat <- fitted(lg_lm_lm.bi_2) 
                   
                        # 3rd stage linear regression Y1 on Y2_hat  
                        lg_lm_lm.bi_3 <- lm(Y1~Y2_hat)  
                        temp.3 <- coeftest(lg_lm_lm.bi_3,  
vcov=vcovHC(lg_lm_lm.bi_3, type = "HC4")) 
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                        est.bi[j] <- temp.3[2,1]  
                        est.bi.se[j] <- temp.3[2,2] 
                        p_value[j] <- temp.3[2,4] 
                        pow[j] <- ifelse(p_value[j]<0.05, 1, 0)   
## if the treatment coefficient=0 was rejected, then symbol as 1 
                        lower.bi[j]<-coefci(lg_lm_lm.bi_3, 
vcov=vcovHC(lg_lm_lm.bi_3, type = "HC4"))[2,1]   
## calculate CI based on robust SE 
                        upper.bi[j]<-coefci(lg_lm_lm.bi_3, 
vcov=vcovHC(lg_lm_lm.bi_3, type = "HC4"))[2,2] 
                         
                        converge.p.bi[j] <- ifelse(parameter[i,3]>lower.bi[j] 
& parameter[i,3]<upper.bi[j], 1, 0) 
                        bias.bi[j] <-est.bi[j]-parameter[i,3]  
                         
                } 
                Bias[i] <- mean(bias.bi) 
                ASE[i] <- mean(est.bi.se) 
                ESE[i] <- sd(est.bi) 
                CP[i] <- sum(converge.p.bi)/1000 
                power_bi[i] <- sum(pow)/1000 
                median_est[i] <- median(est.bi) 
                relative_bias[i] <- mean(bias.bi)/(parameter[i,3]) 
        } 
        return(cbind(Bias,ASE,ESE,CP,power_bi,median_est,relative_bias))   
} 
LG_LM_LM_Bi <- data.frame(present.lg_lm_lm.bi(all.data_bi,new.combi)) 
write.csv(LG_LM_LM_Bi, file="lg_lm_lm_bi.csv") 
 
################################# PLOT ####################################### 
 
require(foreign); require(haven) # to import spss/stata files 
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require(readxl); # read excel files 
require(tidyverse); require(forcats); # for efficiently manipulating datasets 
require(compareGroups) # for descriptive stats 
require(reshape2)  # for reshaping data & plotting 
require(ggplot2); require(ggthemes); require(ggrepel); require(ggpubr); # 
require(ggeffects) # for graphics 
require(gtable); require(gridExtra); require(grid); require(cowplot) # for 
arranging plots 
require(stringr) # for text processing 
 
library(ReporteRs) # for exporting plot to power point 
pd1 <- read_csv("combined_simu_1.csv") #6 x 34 
pd2 <- read_csv("combined_simu_2.csv") #72 x 27 
pd3 <- read_csv("combined_simu_3.csv") #24 x 32 
 
# function to save plot to ppt 
exp2ppt <- function(plot,file,lab="") { 
  mydoc <- pptx() 
  mydoc <- addSlide(mydoc,"Content with Caption") 
  # add caption 
  mydoc <- addTitle(mydoc,lab)   
  # add a plot into mydoc  
  mydoc <- addPlot(mydoc,fun=print,x=plot) 
  writeDoc(mydoc,file) 
} 
## First clean up variable names 
names(pd3) 
pd3_c <- pd3 %>%  
  janitor::clean_names() #24 x 32 
names(pd3) 
 
## Convert to long format for ggplot2 plotting 
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pd3_l <- pd3_c %>% 
  select(-x1) %>%  
  gather(key=metric, value=value 
         ,-n,-pc,-risk_difference 
         ) #672 x 5 
 
## remove empty value 
pd3_l <- pd3_l %>%  
  filter(!is.na(value)) #576 x 5 
 
## convert value to numeric, set inf to NA 
pd3_l <- pd3_l %>%  
  mutate(value=as.numeric(value) 
         ,value=ifelse(value==Inf, NA, value) 
         )  
 
## Create a variable to identify method 
metriclist <- c("bias","relative_bias","ase","ese","cp","power_bi") 
pd3_l <- pd3_l %>%  
  mutate(method=case_when( 
    metric %in% metriclist ~ "LM-LM" 
    ,metric %in% paste0(metriclist,"_1") ~ "LM-LM-X" 
    ,metric %in% paste0(metriclist,"_2") ~ "LG-LM-X" 
    ,metric %in% paste0(metriclist,"_3") ~ "LG-LM-LM-X" 
                          ) 
         ) #576 x 6 
## Standardize the names of the metric 
pd3_l <- pd3_l %>%  
  mutate(metric=str_replace_all(metric,"[_123]","")) #576 x 6 
with(pd3_l,table(metric)) 
 
## Recode to factor for nice labels: 
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rdlev <- pd3_l$risk_difference %>%  
  unique() %>%  
  sort() 
nlev <- pd3_l$n %>%  
  unique() %>%  
  sort() 
pclev <- pd3_l$pc %>%  
  unique() %>%  
  sort() 
methodlev <- c("LM-LM" 
               ,"LM-LM-X" 
               ,"LG-LM-X" 
               ,"LG-LM-LM-X" 
               ) 
 
dsp <- pd3_l %>%  
  mutate(n_f=factor(n 
                    ,levels=nlev 
                    ,labels=paste0("n=",nlev) 
                    ) 
         ,pc_f=factor(pc 
                      ,levels=pclev 
                      ,labels=c("Low\ncompliance" 
                                ,"High\ncompliance" 
                                ) 
                      ) 
         ,method_f=factor(method 
                          ,levels=methodlev 
                          ,labels=methodlev 
                          ) 
         ) 
## Plot relative bias (line plot) 
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fn <- "simulation3_ARB" #filename 
yl <- "Absolute Relative Bias" 
xl <- "Risk Difference" 
pl <- dsp %>%  
  filter(metric=="relativebias") %>%  
  ggplot(aes(x=risk_difference,y=abs(value),group=method_f 
             ) 
         ) + 
  geom_point(aes(shape=method_f) 
             ,alpha=0.7 
             ,size=2 
             # ,position=position_dodge(width=0.05) 
             ) + 
  scale_y_continuous(labels = function(x) sprintf("%4.1f%%",x*100)) + 
  scale_x_continuous(labels = function(x) sprintf("%3.0f%%",x*100) 
                     ,breaks=rdlev 
                     ) +  
  geom_line(aes(color=method_f)) + 
  facet_grid(pc_f~n_f) + 
  theme_pubr() + 
  theme(legend.title = element_blank() 
        # ,legend.direction="vertical" 
        # ,legend.position ="right" 
        ,legend.text = element_text(size=rel(1.2)) 
        ,axis.title=element_text(size=rel(1.25)) 
        ,axis.text = element_text(size=rel(1)) 
        ,strip.text = element_text(size=rel(1.2)) 
        ,panel.spacing = unit(1.5, "lines") 
        ) + 
  labs(x=xl,y=yl) 




1. Perkin, M.R., et al., Randomized Trial of Introduction of Allergenic Foods in Breast-Fed 
Infants. N Engl J Med, 2016. 374(18): p. 1733-43. 
2. Ranganathan, P., C.S. Pramesh, and R. Aggarwal, Common pitfalls in statistical analysis: 
Intention-to-treat versus per-protocol analysis. Perspect Clin Res, 2016. 7(3): p. 144-6. 
3. Jo, B., Model misspecification sensitivity analysis in estimating causal effects of 
interventions with non-compliance. Stat Med, 2002. 21(21): p. 3161-81. 
4. Angrist, J.D., G.W. Imbens, and D.B. Rubin, Identification of Causal Effects Using 
Instrumental Variables. Journal of the American Statistical Association, 1996. 91(434): 
p. 444-455. 
5. Sussman, J.B. and R.A. Hayward, An IV for the RCT: using instrumental variables to 
adjust for treatment contamination in randomised controlled trials. BMJ, 2010. 340: p. 
c2073. 
6. Frangakis, C.E. and D.B. Rubin, Principal stratification in causal inference. Biometrics, 
2002. 58(1): p. 21-9. 
7. Stuart, E.A. and B. Jo, Assessing the sensitivity of methods for estimating principal 
causal effects. Stat Methods Med Res, 2015. 24(6): p. 657-74. 
8. Ertefaie, A., et al., A tutorial on the use of instrumental variables in 
pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2017. 26(4): p. 357-
367. 
9. Hertogh, E.M., et al., Noncompliance in lifestyle intervention studies: the instrumental 
variable method provides insight into the bias. Journal of Clinical Epidemiology, 2010. 
63(8): p. 900-906. 
10. Ye, C., et al., Estimating treatment effects in randomised controlled trials with non-
compliance: a simulation study. BMJ Open, 2014. 4(6): p. e005362. 
11. Palmer, T.M., et al., Adjusting for bias and unmeasured confounding in Mendelian 
randomization studies with binary responses. Int J Epidemiol, 2008. 37(5): p. 1161-8. 
12. Greenland, S., An introduction to instrumental variables for epidemiologists. Int J 
Epidemiol, 2000. 29(4): p. 722-9. 
13. Nagelkerke, N., et al., Estimating treatment effects in randomized clinical trials in the 
presence of non-compliance. Stat Med, 2000. 19(14): p. 1849-64. 
14. Palmer, T.M., et al., Nonparametric bounds for the causal effect in a binary instrumental-
variable model. Stata Journal, 2011. 11(3): p. 345-367. 
15. White, I.R., Uses and limitations of randomization-based efficacy estimators. Stat 
Methods Med Res, 2005. 14(4): p. 327-47. 
16. Cheung, Y.B., A modified least-squares regression approach to the estimation of risk 
difference. Am J Epidemiol, 2007. 166(11): p. 1337-44. 
17. Angrist, J.D., Estimation of limited dependent variable models with dummy endogenous 
regressors: Simple strategies for empirical practice. Journal of Business & Economic 
Statistics, 2001. 19(1): p. 2-16. 
18. Rassen, J.A., et al., Instrumental variable analysis for estimation of treatment effects with 
dichotomous outcomes. Am J Epidemiol, 2009. 169(3): p. 273-84. 
 64 
19. Rubin, D.B., Estimating Causal Effects of Treatments in Randomized and 
Nonrandomized Studies. Journal of Educational Psychology, 1974. 66(5): p. 688-701. 
20. Splawa-Neyman, J., On the application of probability theor ot agricultural experiments. 
Statistical Science, 1923. 5: p. 463-480. 
21. Imai, K., B. Jo, and E.A. Stuart, Commentary: Using Potential Outcomes to Understand 
Causal Mediation Analysis. Multivariate Behavioral Research, 2011. 46(5): p. 861-873. 
22. Gupta, S.K., Intention-to-treat concept: A review. Perspect Clin Res, 2011. 2(3): p. 109-
12. 
23. Adewuyi, T.E., G. MacLennan, and J.A. Cook, Non-compliance with randomised 
allocation and missing outcome data in randomised controlled trials evaluating surgical 
interventions: a systematic review. BMC Res Notes, 2015. 8: p. 403. 
24. Piaggio, G., et al., Reporting of noninferiority and equivalence randomized trials: 
extension of the CONSORT 2010 statement. JAMA, 2012. 308(24): p. 2594-604. 
25. Kim, M.Y., Using the instrumental variables estimator to analyze noninferiority trials 
with noncompliance. J Biopharm Stat, 2010. 20(4): p. 745-58. 
26. Little, R.J., Q. Long, and X. Lin, A comparison of methods for estimating the causal 
effect of a treatment in randomized clinical trials subject to noncompliance. Biometrics, 
2009. 65(2): p. 640-9. 
27. Bellamy, S.L., J.Y. Lin, and T.R. Ten Have, An introduction to causal modeling in 
clinical trials. Clin Trials, 2007. 4(1): p. 58-73. 
28. Hernan, M.A. and J.M. Robins, Instruments for causal inference: an epidemiologist's 
dream? Epidemiology, 2006. 17(4): p. 360-72. 
29. Ten Have, T.R., et al., Intent-to-Treat vs. Non-Intent-to-Treat Analyses under Treatment 
Non-Adherence in Mental Health Randomized Trials. Psychiatr Ann, 2008. 38(12): p. 
772-783. 
30. Carroll, R.J., D. Ruppert, and L.A. Stefanski, Measurement error in nonlinear models. 
Monographs on statistics and applied probability. 1998, Boca Raton: Chapman & 
Hall/CRC. xxiv, 305 p. 
31. Rosner, B., D. Spiegelman, and W.C. Willett, Correction of logistic regression relative 
risk estimates and confidence intervals for measurement error: the case of multiple 
covariates measured with error. Am J Epidemiol, 1990. 132(4): p. 734-45. 
32. JM, W., Introductory Econometrics: A Modern Approach. 2006. 
33. Angrist, J.D., Estimation of Limited Dependent Variable Models With Dummy 
Endogenous Regressors. Journal of Business & Economic Statistics, 2001. 19(1): p. 2-28. 
34. Terza, J.V., A. Basu, and P.J. Rathouz, Two-stage residual inclusion estimation: 
addressing endogeneity in health econometric modeling. J Health Econ, 2008. 27(3): p. 
531-43. 
35. Wooldridge, J.M., Econometric analysis of cross section and panel data. 2002, 
Cambridge, Mass.: MIT Press. xxi, 752 p. 
36. Montgomery, D.C., E.A. Peck, and G.G. Vining, Introduction to linear regression 
analysis. 5th ed. Wiley series in probability and statistics. 2012, Hoboken, NJ: Wiley. 
xvi, 645 p. 
37. Angrist, J.D., Estimation of Limited Dependent Variable Models With Dummy 
Endogenous Regressors: Simple Strategies for Empirical Practice. Journal of Business 
and Economic Statistics, 2001. 19(1,Jan): p. 2-15. 
 65 
38. Jo, B. and E.A. Stuart, On the use of propensity scores in principal causal effect 
estimation. Stat Med, 2009. 28(23): p. 2857-75. 
39. RJ, B. and T. DA, A comparative study of instrumental vriables estimators for nonlinear 
simultaneous models. Journal of the American Statistical Association, 1981. 76(376): p. 
988-995. 
 
